ARCTIC - Operational Feasibility of Appropriate Plasmodium vivax Radical Cure with Tafenoquine or Primaquine After Quantitative G6PD Testing in Thailand
This is a phase IV, observational study. The Principal Investigator is Dr. Chantana Padungtod, M.D., DrPH (Director, Division of Vector Borne Diseases (DVBD)).
Primary Objective:
- to investigate whether P. vivax patients ≥16 years old are treated with tafenoquine (TQ) in accordance with the appropriate level of G6PD enzyme activity.
Secondary Objectives:
- to investigate whether P. vivax patients ≥16 years are treated with daily primaquine (PQ) in accordance with the appropriate level of G6PD enzyme activity;
- to assess the correct application of the radical cure treatment algorithm for P. vivax patients receiving TQ or PQ;
- to measure the frequency of reported drug-induced Acute Haemolytic Anaemia (AHA).